[{"address1": "121 Richmond Street West", "address2": "Penthouse Suite, 1300", "city": "Toronto", "state": "ON", "zip": "M5H2K1", "country": "Canada", "phone": "416 346 7764", "website": "https://www.psyencebiomed.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jody  Aufrichtig", "age": 51, "title": "Co-Founder, Executive Chairman & CEO", "yearBorn": 1974, "fiscalYear": 2025, "totalPay": 216667, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Warwick Ron Corden-Lloyd", "age": 45, "title": "CFO & Director", "yearBorn": 1980, "fiscalYear": 2025, "totalPay": 195000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Neil  Maresky M.D.", "age": 61, "title": "Global Head of Clinical Development", "yearBorn": 1964, "fiscalYear": 2025, "totalPay": 390000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Taryn  Vos", "title": "General Counsel", "fiscalYear": 2025, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1767139200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.7206, "open": 0.6937, "dayLow": 0.64, "dayHigh": 0.7751, "regularMarketPreviousClose": 0.7206, "regularMarketOpen": 0.6937, "regularMarketDayLow": 0.64, "regularMarketDayHigh": 0.7751, "payoutRatio": 0.0, "beta": 0.318, "volume": 514849, "regularMarketVolume": 514849, "averageVolume": 319051, "averageVolume10days": 581208, "averageDailyVolume10Day": 581208, "bid": 0.5374, "ask": 0.8368, "bidSize": 2, "askSize": 2, "marketCap": 4092540, "fiftyTwoWeekLow": 0.625, "fiftyTwoWeekHigh": 79.5, "allTimeHigh": 54562.5, "allTimeLow": 0.625, "fiftyDayAverage": 6.73622, "twoHundredDayAverage": 21.19621, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -5800985, "profitMargins": 0.0, "floatShares": 1869805, "sharesOutstanding": 6388604, "sharesShort": 67332, "sharesShortPriorMonth": 312062, "sharesShortPreviousMonthDate": 1765756800, "dateShortInterest": 1768435200, "sharesPercentSharesOut": 0.0105, "shortRatio": 0.03, "shortPercentOfFloat": 0.0017, "impliedSharesOutstanding": 6388604, "bookValue": 6.339, "priceToBook": 0.10105695, "lastFiscalYearEnd": 1743379200, "nextFiscalYearEnd": 1774915200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -3941597, "trailingEps": -62.4, "lastSplitFactor": "16:100", "lastSplitDate": 1768867200, "enterpriseToEbitda": 1.399, "52WeekChange": -0.99121916, "SandP52WeekChange": 0.1575526, "quoteType": "EQUITY", "currentPrice": 0.6406, "recommendationKey": "none", "totalCash": 7149985, "totalCashPerShare": 3.819, "ebitda": -4145455, "totalDebt": 0, "quickRatio": 7.766, "currentRatio": 8.09, "returnOnAssets": -0.34442002, "returnOnEquity": -0.74286, "freeCashflow": -4006023, "operatingCashflow": -4247508, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "PBM", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "esgPopulated": false, "marketState": "CLOSED", "corporateActions": [{"header": "Delisting", "message": "PBM was delisted effective Jan. 23, 2026", "meta": {"eventType": "DELISTING", "dateEpochMs": 1769144400000}}], "postMarketTime": 1769820566, "regularMarketTime": 1769806801, "exchange": "NCM", "messageBoardId": "finmb_698500412", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1639146600000, "postMarketChangePercent": 4.3709016, "postMarketPrice": 0.6686, "postMarketChange": 0.027999997, "regularMarketChange": -0.07999998, "regularMarketDayRange": "0.64 - 0.7751", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 319051, "fiftyTwoWeekLowChange": 0.015600026, "fiftyTwoWeekLowChangePercent": 0.024960041, "fiftyTwoWeekRange": "0.625 - 79.5", "fiftyTwoWeekHighChange": -78.8594, "fiftyTwoWeekHighChangePercent": -0.9919421, "fiftyTwoWeekChangePercent": -99.12192, "epsTrailingTwelveMonths": -62.4, "fiftyDayAverageChange": -6.0956197, "fiftyDayAverageChangePercent": -0.9049021, "twoHundredDayAverageChange": -20.55561, "twoHundredDayAverageChangePercent": -0.9697776, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "longName": "Psyence Biomedical Ltd.", "shortName": "Psyence Biomedical Ltd.", "regularMarketChangePercent": -11.101857, "regularMarketPrice": 0.6406, "ipoExpectedDate": "2024-01-26", "cryptoTradeable": false, "displayName": "Psyence Biomedical", "trailingPegRatio": null, "__fetch_time": "2026-01-31"}]